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Summary. — The breast cancer (BC) disease is characterized by a wide hetero-
geneity at both clinical and molecular level, showing distinct subtypes with different
clinical outcomes. Thus, the choice of the therapeutic plan, such as the type of ra-
diotherapy (RT) need to take into account this complexity. Indeed, the proton
therapy (PT) shows a medical benefit compared to conventional X-ray RT, as re-
gards the localized delivery of the radiation dose sparing health tissues, but few data
regarding proton-induced molecular changes are currently available. The aim of this
study was therefore to investigate the production of immunological molecules and
gene expression profiles induced by proton irradiation on BC cell lines. Clonogenic
survival assay, luminex assay and cDNA microarray gene expression analyses were
performed both in the non-tumorigenic MCF10A cell line and in two tumorigenic
MCF7 and MDA-MB-231 cell lines, following irradiation with 0.5, 2 and 9 Gy of
clinical proton beams. We found that proton irradiation induced gene expression
changes useful to define a cell line and dose-dependent gene signatures. The lack
of molecular data in the literature can be filled by data here presented that could
represent a useful tool to better understand the molecular mechanisms elicited by
protons predicting the treatment outcome.
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1. – Introduction
The development of molecularly based signatures by gene expression profiling as
biomarkers of disease is a promising strategy also to predict the response to the radiation
treatment in the breast cancer (BC) disease [1, 2]. Specific assays, such as Onco-
typeDx, MammaPrint and Prosigna have been applied so far, modifying the conven-
tional chemotherapy. The same goal can be reached for the evaluation of the response to
the radiation treatment that is currently applied without taking account of the molec-
ular characteristics and tumour heterogeneity [3, 4]. In this scenario, the application of
the particle therapy requires the knowledge of radiation-induced biological mechanisms
as well as of well-known physical beam features. Indeed, the accelerated proton beams
showed potential advantages over conventional (photon-electron-based) radiation for BC,
with a more localized delivery of the radiation dose on the tumor target, sparing heart
and lungs surroundings [5-7]. However, these physical advantages can encourage stud-
ies evaluating proton-induced molecular changes, which are currently considered to be
underexplored. In our previous studies we demonstrated that irradiation can influence
the tumour progression control, since inflammatory factors related to the cell fate were
specifically involved after ionizing radiation (IR) exposures [8, 9]. Therefore, the pro-
ton therapy (PT) effects need to be investigated at molecular level in order to identify
biomarkers and gene signatures in response to the proton radiation treatment in BC.
In this study, the MCF10A mammary non-tumorigenic cell line, MCF7 and MDA-
MB-231 BC cell lines were irradiated with protons beam at doses of 0.5, 2 and 9 Gy. The
aim was to compare the cell loss of the reproductive capacity, radiation-induced gene
expression profile (GEPs), cytokines, chemokines and growth factors produced by the
three cell lines with different aggressive phenotypes. Our results highlighted the global
molecular and immunological response of tumorigenic and non-tumorigenic BC cell lines
to PT.
2. – Materials and methods
2.1. Proton irradiation set up. – Proton irradiations were performed at INFN-LNS
(Catania) using the clinical CATANA facility [10-12]. The protons were accelerated by a
superconductive cyclotron, the beam was converted into a uniform clinical beam able to
cover the entire target region passing through different passive elements, as previously
reported [8]. Flasks were irradiated in the upright position facing the collimated beam
exit by delivering separate shots: to cover entirely the flask surface, an ad hoc remotely
controlled positioning system ensured that after each shot, the flask was moved so that
the next shot would hit the adjacent area. Cell irradiations were conducted placing the
cells in the middle of the Spread-Out Bragg Peak (SOBP, 1 cm width), to simulate a
clinical condition, with dose values of 0.5, 2 and 9 Gy and a dose rate of 15 Gy/min.
2.2. Cell culture and clonogenic survival assays. – The human non-tumorigenic breast
epithelial MCF10A cell line and the human breast adenocarcinoma MCF7 and MDA-
MB-231 cell lines were purchased from the American Type Culture Collection (ATCC)
and cultured according to the manufacturer’s instructions (ATCC, Manassas, VA) as
previously reported [9]. Cells were maintained in culture under standard growth condi-
tions. Forty-eight hours before irradiation, cells were seeded in T25 tissue culture flasks
and maintained at subconfluence. The surviving fraction (SF) was evaluated by a clono-
genic assay performed as previously described [13, 14]. Untreated cells were used as a
control to calculate the plating efficiency (PE). Cells were allowed to form colonies under
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normal cell culture conditions for 10–12 days and then were fixed and stained for 30 min
with methanol and 0.5% crystal violet (both from Sigma-Aldrich, St. Louis, MO, USA).
Colonies with more than 50 cells were counted both manually under a phase-contrast
microscope and with a software developed at the CNR-IBFM [15].
2.3. Cytokine, chemokine and growth factor analysis by Luminex assay . – The assay
was performed using the Luminex system according to the manufacturer’s instructions
(BioRad, Munchen, Germany) as previously described [9].
At 24, 48 and 72 h post-irradiation, irradiated conditioned media (ICM) were
collected.
Untreated cells for each cell line were grown under the same experimental conditions
and the conditioned medium (CM) was collected and used as a control to compare with
treated samples. In addition, the blank controls, i.e., the complete media without cells
incubated under the same experimental conditions, were collected. The assay tests the
following panel of 17 cytokines chemokines and growth factors: IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17, IFN-c, TNF-a, monocyte chemoattrac-
tant protein-1 (MCP-1), macrophage inflammatory protein-1b (MIP-1b), granulocyte-
macrophage colony-stimulating factor (GM-CSF), and granulocyte colony stimulating
factor (G-CSF). An eight-point standard curve for every molecule was used and the
reported data were normalised with respect to an untreated sample. Data were ana-
lyzed using the Bio-Plex Manager software (BioRad). All data are reported as means of
duplicate measurements.
2.4. Gene expression profiling by cDNA microarray analysis. – Whole-genome cDNA
microarray expression analyses were conducted using the Agilent’s Microarray Platform
(Santa Clara, CA, USA) as previously described [13, 14]. MCF10A, MCF7 and MDA-
MB-231 cells were collected 24 hr after irradiation and the pellet was stored immedi-
ately at −80 ◦C. The total RNA was extracted from the pellet using Trizol and the
RNeasy mini kit according to the manufacturer’s instructions (Invitrogen). Qualitative
and quantitative analyses of isolated RNA, labeling with Cy5 dye and with Cy3 dye,
hybridization onto Whole Human Genome 4 × 44K microarray GeneChips containing
all known genes and transcripts of an entire human genome, were conducted as previ-
ously described [13,14]. Background correction of acquired images, normalization of the
gene expression profiles (GEPs) and statistical data analysis were performed using the
Feature Extraction and GeneSpring software (Agilent Technologies). Statistically sig-
nificant differences were calculated by Students t-test and the significance level was set
at p < 0.05. Differentially expressed genes were identified if they showed a fold change
(FC) of at least 2 with a p-value < 0.05 compared to untreated MCF10A, MCF7 and
MDA-MB-231 cells used as reference sample. The gene expression data have been de-
posited in the National Center for Biotechnology Information Gene Expression Omnibus
(GEO) [16] (http://www.ncbi.nlm.nih.gov/geo). Microarray data also are available
in compliance with Minimum Information About a Microarray Experiment (MIAME)
standards.
2.5. Pathway analyses of GEP lists. – Pathway analyses were performed using the
Reactome tool, in order to understand the biological meaning behind the lists of dif-
ferentially expressed gene obtained by GEP analysis (https://reactome.org/). The
most representative and significantly changed pathways and networks were selected and
analyzed.
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3. – Results
3.1. Cell survival.. – The clonogenic assay results revealed varying radiosensitivity
according to the breast cell lines used. In particular, the SFs obtained following 0.5, 2
and 9 Gy are as follows: MCF10A cells: 0.78 ( ± 0.08); 0.44 ( ± 0.09); 0.050 ( ± 0.09);
MCF7 cells: 0.67 ( ± 0.13); 0.38 ( ± 0.15); 0.0385 ( ± 0.0007); MDA-MB-231 cells: 0.81
( ± 0.11); 0.53 ( ± 0.10); 0.040 ( ± 0.01), as shown in fig. 1.
3.2. Immunological molecules profiles secreted after radiation treatment . – In this work
we studied the cytokines, chemokines and growth factors profiles of non-tumorigenic
mammary epithelial MCF10A cells and tumorigenic BC MCF7 and MDA-MB-231 cell
lines, produced after proton irradiation with 0.5, 2 and 9 Gy doses, and assayed 24, 48
and 72 h after radiation exposures. The results of these assays are displayed in fig. 2. In
the MCF10A cell line, a generalized cytokine down-regulation was observed 24 h post-
treatment in each of the dose configuration tested, but a slight increase of cytokines
secretion after 48 and 72 h post-irradiation was observed. In particular, all the molecules
assayed showed an increased secretion 48 h post-treatment with 9 Gy, whereas a cytokine
increase was found for all the three doses delivered at 72 h post-irradiation. These results
suggest a time- and dose-dependent secretion of immunological molecules.
Regarding the two BC cell lines, we observed differences in the expression profiles
of secreted molecules. The MCF7 cells showed a very low secretion of immunological
factors in the ICM after radiation exposure, indeed only 8 out of the 15 immunological
factors tested were detectable. These outcomes are in line with the literature data and
with the results described by our group following electron radiation treatments in the
MCF7 cells [9-17]. On the contrary, in the MDA-MB-231 cell line an earlier activation of
almost all the immunological factors was observed in the ICM, effect that became more
consistent especially 48 and 72 hours post-treatments. Therefore, MDA-MB-231 cells
have revealed the strongest pro-inflammatory secretion profile compared to the other cell
lines tested.
Fig. 1. – Surviving fractions of proton irradiation response in BC cell lines MCF10A, MCF7
and MDA-MB-231. Bar diagrams of the surviving fraction are in percentage. The data are
mean ± SD of three independent experiments.
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Fig. 2. – Overview of immunological proton irradiation response in BC cell lines MCF10A,
MCF7 and MDA-MB-231.
3.3. Gene expression profiling (GEP) by cDNA microarray and pathway analysis. – A
two-color cDNA microarray-based gene expression analysis on the three breast cell lines
treated with the same proton irradiation set-up reported above (i.e., 0.5, 2 and 9 Gy of
proton beam doses) was performed. GEPs of irradiated cells were compared to those
of untreated cells, used as reference samples. A comparative differential gene expression
analysis showed that multiple genes were significantly altered, at least 2-fold or greater,
compared to untreated cells (fig. 3).
In order to select and group transcripts according to their involvement in specific bio-
logical pathways the Reactome tool was used [18]. For each cell line analyzed, deregulated
Fig. 3. – Number of deregulated genes in MCF10A, MCF7 and MDA-MB-231 cell lines proton
irradiated with doses of 0.5, 2 and 9 Gy.
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Fig. 4. – Specific 8-gene signature based on 27, 51 and 70 common dose-related genes in MCF7
and MDA-MB-231 cell lines exposed to 0.5, 2 and 9 Gy.
genes were unique and common between all the three dose configuration tested, defining
gene expression profiles responsible for the activation of intracellular mechanisms and
pathways able overall to respond to stress, such as those induced by IR. In particular,
MCF10A cells revealed a gene response to irradiation with the activation of pathways
related to inflammation, lipid metabolism and detoxification process. In MCF7 cells,
a radiation-induced gene signature showed the involvement of general pathways not di-
rectly related to such stress response. The MDA-MB-231 cells showed the activation of
pathways specifically induced in response to IR and related to several processes, such
as gene transcription, apoptosis, inflammatory and anti-inflammatory response. In ad-
dition, we evaluated the differently expressed genes and pathways altered in the MCF7
and MDA-MB-231 BC cell lines, based on the delivered dose. Common and unique genes
were deregulated in BC cells after proton irradiation using the same dose, able to define
a proton dose-related gene signatures. Finally, a specific gene signature shared between
BC cells exposed to the three doses of proton irradiation was identified, as shown in
fig. 4.
3.4. Discussion. – Nowadays, the PT showed potential advantages over photon-
electron-based conventional RT for BC treatment, with a more localized delivery of the
radiation dose on the tumor target, sparing heart and lungs surroundings [5-7]. However,
studies evaluating proton-induced cell and molecular changes must be implemented, since
this topic is considered almost completely unexplored, in order to the define molecularly
based signatures to predict the response to the radiation treatment in BC.
The aim of this study was to identify gene signatures and immunological molecule
profiles of breast cell lines treated with PT. Following the proton beam irradiation with
doses of 0.5, 2 and 9 Gy on the non-tumorigenic MCF10A and tumorigenic MCF7 and
MDA-MB-231 BC cell lines, a panel of cytokines, chemokines and growth factors was
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analyzed by the Luminex assay. In addition, the whole genome gene expression profiling
by cDNA microarray analysis was performed.
Time– and cell-line–dependent cytokine signatures were observed for all the three
breast cell lines tested. In particular, among the three cell lines, MDA-MB-231 cells
expressed immune response profiles in a time-dependent manner, with a strong activation
of pro-inflammatory factors. The secretion IR-induced of cytokines, chemokines and
growth factors can modulate the immune system towards survival/cell death balance
and/or the senescence process in a highly specific way. These results are in line with
those obtained by our group on the same breast cell lines following the electron beam
irradiation [9].
We also analyzed GEPs induced by proton irradiation with the same doses, describing
specific dose– and cell-type–dependent gene signatures. Each cell line revealed a specific
alteration of a set of factors controlling several cellular processes, such as the cell death
processes and inflammation. Through inflammation these cells can regulate intracellular
mechanisms involved in stress radiation cell response. Among the GEPs, we selected 8
common deregulated genes (8-gene signature) in BC cells after 0.5, 2 and 9 Gy, which
could represent specific biomarkers of the proton cell response.
In conclusion, our data confirm that the cell response to radiation is highly the het-
erogeneous resulting cell-line– and dose–dependent. The knowledge of radiation-induced
molecular mechanisms is very useful for the future realization of personalized proton
therapy protocols in combination with targeted therapies.
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